EUCTR2007-007273-23-NL
Active, not recruiting
Not Applicable
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine combined with Protocolized Surgery in Resectable Gastric Cancer - DoCCS
Jeroen Bosch Hospital0 sitesDecember 11, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Jeroen Bosch Hospital
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Ib\-IVa histological proven resectable gastric adenocarcinoma
- •WHO \< or \= 1
- •Age \> or \= 18 years
- •No prior radio\- or chemotherapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Ia gastric cancer
- •Other histological type than adenocarcinoma
- •Distant metastases
- •Inoperable patients
- •Other current serious illness or medical conditions
- •Known hypersensitivity to Docetaxel/Taxotere
- •Pregnant or lactating women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer An IKZ-based phase II feasibility studygastric cancergastric carcinoma100179901001799110017998NL-OMON31603Jeroen Bosch Ziekenhuis50
Recruiting
Not Applicable
A study to investigate the feasibility of chemotherapy prior to surgery and protocolized surgery in resectable stomach cancer.Resectable/curable gastric cancerNL-OMON20157dr K. Bosscha, surgeondr J.F.M. Pruijt, oncologistdrs A.E. Dassen, resident in training for surgery50
Recruiting
Phase 2
eoadjuvant DOS treatment for advanced esophageal cancerJPRN-jRCTs041210023Kodera Yasuhiro45
Active, not recruiting
Phase 1
A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis®) in Patients with Localized Myxoid / Round Cell Liposarcomaocalized myxoid / round cell liposarcoma previously untreated with chemotherapy or radiationMedDRA version: 9.1Level: LLTClassification code 10024630Term: Liposarcoma non-metastaticEUCTR2007-000035-25-FRPharma Mar, S.A.22
Active, not recruiting
Not Applicable
A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcomaocally advanced (Stage III) myxoid / round cell liposarcoma previously untreated with chemotherapy or radiationMedDRA version: 9.1Level: LLTClassification code 10024630Term: Liposarcoma non-metastaticEUCTR2007-000035-25-DEPharma Mar, S.A.22